PROTEOBLOOD_POCTEFA

Optimize, share and exploit a set of cutting-edge technologies and resources, for the study of protein homeostasis in two prevalent subtypes of leukemia and lymphoma and to generate innovative transferable tools and technologies. Towards the development of personalized medicines against hematological cancer. To achieve this goal, the network will jointly establish a collection of patient-derived study models (organoids and xenografts) with the ability to recreate ex vivo the tumor microenvironment. State-of-the-art proteomics approaches, associated with the analysis of systems biology and the design of small molecules, will allow the complete characterization of proteopathies and the development of effective and safe therapies that will be validated in organoid and xenograft collections. PROTEOblood will thus promote Technological Development, cross-border cooperation and knowledge exchange, facilitating the optimization of existing infrastructures and resources.